ABSTRACT
The management of scleroderma is essentially aimed at the disease complications as and when these arise. Management of systemic sclerosis (SSc) may prevent progressive systemic fibrosis and microvascular damage; at the same time, judicious management of the complications arising due to the involvement of various organs including skin ensures a better quality of life. Prostanoids, Phosphodiesterase-5 inhibitors, calcium channel blockers, and endothelin receptor antagonists have been recommended in the management of digital ulcers in SSc. Management requires modification of the patient’s eating schedule; frequent small meals are recommended rather than the usual heavy ones at long intervals. The recommendations for the management of SSc-related pulmonary arterial hypertension (PAH) are essentially in line with the management guidelines for PAH. Musculoskeletal manifestations are benefited from the immunosuppressive therapy, and other additional symptomatic treatment is similar to that employed in general.
